Summary
Rating agencies Moody's and S&P have assigned investment-grade ratings to Sun Pharmaceutical Industries following its proposed USD 11.75-billion acquisition of US-based Organon & Co. The acquisition is expected to significantly bolster Sun Pharma's revenue and market position, with the transaction anticipated to close by March 2027.